ProCE Banner Activity

CheckMate 227 Part 1: 4-Yr Update of First-line Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy in Advanced NSCLC

Slideset Download
Conference Coverage
First-line nivolumab plus ipilimumab continued to provide durable clinical benefit in patients with advanced NSCLC regardless of PD-L1 expression level with extended follow-up.

Released: June 10, 2021

Expiration: June 09, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme